WO2000040604A3 - PROCEDES ET COMPOSITIONS PERMETTANT DE MODULER LA LIBERATION DE CYTOKINES PAR LES CELLULES A EXPRESSION DE αEβ¿7? - Google Patents

PROCEDES ET COMPOSITIONS PERMETTANT DE MODULER LA LIBERATION DE CYTOKINES PAR LES CELLULES A EXPRESSION DE αEβ¿7? Download PDF

Info

Publication number
WO2000040604A3
WO2000040604A3 PCT/US1999/030992 US9930992W WO0040604A3 WO 2000040604 A3 WO2000040604 A3 WO 2000040604A3 US 9930992 W US9930992 W US 9930992W WO 0040604 A3 WO0040604 A3 WO 0040604A3
Authority
WO
WIPO (PCT)
Prior art keywords
αeβ7
methods
compositions
expressing cells
cytokine release
Prior art date
Application number
PCT/US1999/030992
Other languages
English (en)
Other versions
WO2000040604A2 (fr
Inventor
Michael B Brenner
Christina M Parker
Michelle Woldemar Carr
Anu Arya
Original Assignee
Brigham & Womens Hospital
Michael B Brenner
Christina M Parker
Michelle Woldemar Carr
Anu Arya
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital, Michael B Brenner, Christina M Parker, Michelle Woldemar Carr, Anu Arya filed Critical Brigham & Womens Hospital
Priority to AU23904/00A priority Critical patent/AU2390400A/en
Publication of WO2000040604A2 publication Critical patent/WO2000040604A2/fr
Publication of WO2000040604A3 publication Critical patent/WO2000040604A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/06—Methods of screening libraries by measuring effects on living organisms, tissues or cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/53—Colony-stimulating factor [CSF]
    • G01N2333/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/57—IFN-gamma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne des procédés et des compositions permettant de moduler la libération de cytokines par les cellules à expression de αEβ7. L'invention concerne également des polypeptides de liaison et autres molécules qui se lient sélectivement à αEβ7, bloquant ou améliorant la réponse en cytokines Th2 par les cellules considérées. Par ailleurs, les antagonistes et les agonistes décrits dans l'invention sont utiles dans les essais de criblage visant à identifier les principaux composés pharmaceutiques capables de moduler la libération de cytokines par les cellules en question. L'invention concerne enfin des procédés et des compositions pharmaceutiques permettant de modifier in vitro et in vivo la réponse en cytokines Th2 par lesdites cellules.
PCT/US1999/030992 1999-01-08 1999-12-28 PROCEDES ET COMPOSITIONS PERMETTANT DE MODULER LA LIBERATION DE CYTOKINES PAR LES CELLULES A EXPRESSION DE αEβ¿7? WO2000040604A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU23904/00A AU2390400A (en) 1999-01-08 1999-12-28 Methods and compositions for modulating cytokine release by alphaebeta7-expressing cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11505599P 1999-01-08 1999-01-08
US60/115,055 1999-01-08

Publications (2)

Publication Number Publication Date
WO2000040604A2 WO2000040604A2 (fr) 2000-07-13
WO2000040604A3 true WO2000040604A3 (fr) 2000-11-09

Family

ID=22359050

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/030992 WO2000040604A2 (fr) 1999-01-08 1999-12-28 PROCEDES ET COMPOSITIONS PERMETTANT DE MODULER LA LIBERATION DE CYTOKINES PAR LES CELLULES A EXPRESSION DE αEβ¿7?

Country Status (2)

Country Link
AU (1) AU2390400A (fr)
WO (1) WO2000040604A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104710532A (zh) * 2004-09-03 2015-06-17 健泰科生物技术公司 人源化的抗-β7拮抗剂及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5594120A (en) * 1994-02-18 1997-01-14 Brigham And Women's Hospital, Inc. Integrin alpha subunit
US5610281A (en) * 1994-05-03 1997-03-11 Brigham & Women's Hospital, Inc. Antibodies for modulating heterotypic E-cadherin interactions with human T lymphocytes
WO1997025423A1 (fr) * 1996-01-05 1997-07-17 Icos Corporation Modulateurs cytoplasmiques de liaison integrine
WO1998025144A1 (fr) * 1996-12-06 1998-06-11 The Scripps Research Institute Procedes et lignees cellulaires destines a l'identification de regulateurs de l'activation de l'integrine et compositions identifiees a l'aide de ces procedes et lignees cellulaires
JPH10218790A (ja) * 1997-02-10 1998-08-18 Kazuo Tsubota 分泌腺細胞とリンパ球との接着阻害剤

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5594120A (en) * 1994-02-18 1997-01-14 Brigham And Women's Hospital, Inc. Integrin alpha subunit
US5610281A (en) * 1994-05-03 1997-03-11 Brigham & Women's Hospital, Inc. Antibodies for modulating heterotypic E-cadherin interactions with human T lymphocytes
WO1997025423A1 (fr) * 1996-01-05 1997-07-17 Icos Corporation Modulateurs cytoplasmiques de liaison integrine
WO1998025144A1 (fr) * 1996-12-06 1998-06-11 The Scripps Research Institute Procedes et lignees cellulaires destines a l'identification de regulateurs de l'activation de l'integrine et compositions identifiees a l'aide de ces procedes et lignees cellulaires
JPH10218790A (ja) * 1997-02-10 1998-08-18 Kazuo Tsubota 分泌腺細胞とリンパ球との接着阻害剤

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
B LUDVIKSSON ET AL: "Administration of mAb against alphaEbeta7 prevents and ameliorates immunization-induced colitis in IL-2-/- mice", JOURNAL OF IMMUNOLOGY,US,THE WILLIAMS AND WILKINS CO. BALTIMORE, vol. 162, no. 8, 15 April 1999 (1999-04-15), pages 4975 - 4982-4982, XP002129086, ISSN: 0022-1767 *
C JORGENSEN ET AL: "Inhibition of human mucosal lymphocytes migration in rheumatoid synovium engrafted in SCID mice by antibodies against LFA-1 and alphaEbeta7 adhesion molecules", ARTHRITIS AND RHEUMATISM,US,LIPPINCOTT, PHILADELPHIA, vol. 37, no. 9, SUPPL, September 1994 (1994-09-01), pages 5220, XP002129083, ISSN: 0004-3591 *
CEPEK K.L. ET AL.: "Adhesion between epithelial cells and T lymphocytes mediated by E-cadherin and the alpha-E-beta-7 integrin", NATURE, vol. 372, 1994, pages 190 - 193, XP002137720 *
JORGENSEN C ET AL: "Overexpression of integrin alpha-E-beta-7 on synovial fluid lymphocytes in rheumatoid arthritis and its regulation by sulfasalazine, sulfapyridine, 5-ASA and methotrexate", ARTHRITIS AND RHEUMATISM,US,LIPPINCOTT, PHILADELPHIA, vol. 37, no. 9, SUPPL, 1994, pages S255, XP002138709, ISSN: 0004-3591 *
PANG M ET AL: "UP-REGULATION OF ALPHAEBETA7, A NOVEL INTEGRIN ADHESION MOLECULE, ON T CELLS FROM SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH SPECIFIC EPITHELIAL INVOLVEMENT", ARTHRITIS AND RHEUMATISM,US,LIPPINCOTT, PHILADELPHIA, vol. 41, no. 8, August 1998 (1998-08-01), pages 1456 - 1463-1463, XP000867228, ISSN: 0004-3591 *
PARKER C.M. ET AL.: "A family of beta-7 integrins on human mucosal lymphocytes", PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 1294 - 1298, XP002137721 *
PATENT ABSTRACTS OF JAPAN vol. 1998, no. 13 30 November 1998 (1998-11-30) *
RUSSELL G J ET AL: "DISTINCT STRUCTURAL AND FUNCTIONAL EPITOPES OF THE ALPHAE BETA7 INTEGRIN", EUROPEAN JOURNAL OF IMMUNOLOGY,DE,WEINHEIM, vol. 24, 1 November 1994 (1994-11-01), pages 2832 - 2841, XP000672907, ISSN: 0014-2980 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104710532A (zh) * 2004-09-03 2015-06-17 健泰科生物技术公司 人源化的抗-β7拮抗剂及其应用
CN104710532B (zh) * 2004-09-03 2019-01-18 健泰科生物技术公司 人源化的抗-β7拮抗剂及其应用

Also Published As

Publication number Publication date
AU2390400A (en) 2000-07-24
WO2000040604A2 (fr) 2000-07-13

Similar Documents

Publication Publication Date Title
WO2001062942A3 (fr) Materiaux et procedes impliquant un hybride d"adn de facteur de croissance de l"endothelium vasculaire et de proteines
AU7703400A (en) Substrates and screening methods for transport proteins
WO2006083276A3 (fr) Polypeptides et conjugues interferon-alpha
WO2004035603A3 (fr) Anticorps se liant au recepteur de l'erythropoietine
WO2005113592A3 (fr) Polypeptides et conjugues interferon-alpha
EP1399547A4 (fr) PROCEDES ET DES COMPOSITIONS UTILISANT LES PROTEINES GFP i RENILLA /i ET i PTILOSARCUS /i
EP2290079A3 (fr) Facteurs neurotrophiques
WO2009038760A3 (fr) Protéines de liaison à un antigène gm-csf humain
NO20043257D0 (no) Innkapslede bindingsproteiner som biosensorer
WO2006073941A3 (fr) Polypeptides de liaison a la br3 et leurs utilisations
EP1741713A3 (fr) Biphényl-sulfonamides comme antagonistes jumalées des récepteurs endothélines.
WO2004035170A3 (fr) Composition permettant de separer des molecules
WO1999035495A3 (fr) Lignees cellulaires recombinees pour le criblage de medicaments
WO2002077210A3 (fr) Methodes de culture du circovirus
EP1967590A3 (fr) Constructions d'emballages lentivirus
AU2334301A (en) Chemokine receptor binding heterocyclic compounds
WO2006087163A3 (fr) Nouvelles methodes in vitro destinees a l'etude de recepteurs reconnaissant des composes volatils
WO2001034824A3 (fr) Procedes et compositions contenant des proteines fluorescentes vertes (gfp) de renilla
WO2004046365A3 (fr) Polypeptides et conjugues interferon-alpha
WO2005028497A3 (fr) Peptides se liant a des recepteurs derives de proteines sars s
WO2001049721A3 (fr) Nouveaux genes bacteriens et proteines qui sont essentielles pour la viabilite cellulaire et leurs utilisations
WO2002049625A3 (fr) Composés affectant l'expression de cd83, compositions pharmaceutiques à base de telles composés, et procédés permettant d'identifier ces composés
WO2003095606A3 (fr) Sous-population de lymphocyte t regulant l'immunite des intestins
EP1929015A4 (fr) Construction rapporteur double fluorescence et dosage servant a mesurer un recodage traductionnel
WO2004003149A8 (fr) Polypeptides cngh0005, anticorps, compositions, methodes et utilisations

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase